Skip to main content
Category

News

Jlabs 2024 250

WBJ: Johnson & Johnson’s D.C. incubator to leave Children’s National Hospital’s Walter Reed campus

By News

Jlabs 2024 250By Sara Gilgore – Staff Reporter, Washington Business Journal – Johnson & Johnson Innovation’s D.C. incubator is preparing to leave Children’s National Hospital’s Research and Innovation Campus at Walter Reed.

J&J’s innovation arm informed the pediatric health system that it intends to “begin transitioning site operations and management for select JLabs locations back to site owners in 2026,” Dr. Nathan Kuppermann, Children’s National’s chief academic officer, wrote Tuesday in an internal memo to staff, obtained by the Washington Business Journal.

The JLabs incubator will begin winding down its operations at that site ahead of a planned departure in January 2026, according to the email. Kuppermann said the change “does not alter” the system’s vision or long-term goals and, rather, “opens the door to new possibilities for growth and innovation” at the campus.

Read More
Phlow

Phlow Announces Close of $37M Series C Financing to Accelerate Modern Medicine Development and Manufacturing in America

By News

PhlowRichmond, VA, July 22, 2025 (GLOBE NEWSWIRE) — Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced the successful close of its Series C financing round at an increased valuation from previous funding. The $37 million raise supports the Company’s mission of helping brilliant minds bring medicines to life through advanced development and manufacturing in America. The growing Company’s Series C round was led by Align Private Capital LLC, a woman-owned investment firm which manages private family office direct investment vehicles, and was supported by additional new and follow-on investors.

Read More
astrazeneca logo

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

By News

astrazeneca logoAstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.

The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.

Read More
biopharmadive

BioPharmaDive: Biotech startup funding dried up in second quarter, HSBC finds

By News

biopharmadive7/17/2025 –  – Even before HSBC’s report, there were signs of a biotech funding slowdown.

Research the investment bank Jefferies published in May and again in June found a substantial pullback in financing in public companies. Private rounds tracked by BioPharma Dive have gotten larger, but are fewer in number, too, as venture firms appear to be favoring surer bets. Initial public offerings have largely been on pause since the middle of February.

HSBC’s findings detail the fallout for drug startups more specifically. A combination of worries over pharmaceutical tariffs, research funding cuts and leadership changes at public health agencies drove a slump that led to startups’ worst quarter in terms of seed or Series A funding rounds since 2023, according to Jonathan Norris, a managing director at HSBC Innovation Banking.

Read More
TedcoZero

TEDCO Invests in Zero Point Five Therapeutics

By News

TedcoZeroCOLUMBIA, Md., (July 21, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent Venture Funds investment for nearly $350,00 in Zero Point Five Therapeutics. TEDCO’s evergreen Venture Funds are committed to investing in and advancing early-stage technology and life sciences companies across Maryland. These funds provide startups with access to a seasoned team dedicated to supporting their entrepreneurial growth and success.

Read More
3Days3Events

3 Days, 1 Region, Endless Opportunity: What to Expect at BHCR Week 2025

By News

3Days3EventsPlanning is well underway for BioHealth Capital Region Week 2025, and hundreds of attendees have already registered for the Forum taking place September 23–25 at US Pharmacopeia in Rockville, Maryland. Now in its 11th year, this free, three-day event brings together the people shaping the future of biohealth, including industry leaders, entrepreneurs, investors, government officials, and academic researchers, for insight, collaboration, and deal-making.

With this year’s theme, “Where Human and Artificial Intelligence Converge in the BioHealth Industry,” the program offers a timely look at how new technologies are transforming the entire innovation pipeline—from early-stage research through commercialization and patient impact.

The week opens with the BioHealth Capital Region Forum on September 23 and 24. This two-day event will feature keynote speakers, panels, and networking focused on industry trends, workforce strategies, and the impact of AI on research, development, and clinical decision-making. Whether you’re looking for policy updates, partnering opportunities, or inspiration, the Forum delivers valuable insight and access. Register today at https://bit.ly/BHCRWeek2025.

Read More
i mab biopharma large

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

By News

i mab biopharma largeROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig.

Read More
60degrees logo rgb logo

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

By News

60degrees logo rgb logoWASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the pricing of a public offering of 2,631,578 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying Series A-1 warrants to purchase up to 2,631,578 shares of common stock and short-term Series A-2 warrants to purchase up to 2,631,578 shares of common stock, at a combined offering price of $1.90 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants.

Read More
Gain

Gain Therapeutics Announces Proposed Public Offering

By News

GainBETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

Read More
CFF Logo 250

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

By News

CFF Logo 250BETHESDA, Md.–(BUSINESS WIRE)–Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis (CF).

Prime Medicine uses a gene editing technology called prime editing — a technology that enables a wide range of modifications to the DNA with a high degree of precision. The company — founded by Drs. David Liu and Andrew Anzalone, who pioneered the development of this unique editing technology — is investigating whether prime editing could treat several diseases, including CF.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.